Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
Treatments Hub

Verified prices

All verified prices
Science10 min read

Mounjaro vs Ozempic for Weight Loss (2026): Full Comparison

Mounjaro vs Ozempic - which GLP-1 medication is better for weight loss? We compare clinical results, side effects, dosing, cost, insurance, and how to get them online.

Updated September 15, 2026

Medically reviewed on

How we review

The quick answerThey are not the same drug: Mounjaro (tirzepatide) targets two hormone receptors and produced up to 22.5% average weight loss in trials, versus ~15% for Ozempic (semaglutide). Ozempic's compounded version is cheaper - verified from $41/month versus $71 for tirzepatide - and both require a prescription from a licensed provider.Prices verified on each provider’s site as of November 3, 2026.

Mounjaro vs Ozempic: Key Differences at a Glance

Two unbranded injection pens, navy and blue, on either side of a small empty balance scale on a desk, comparing tirzepatide and semaglutide

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both injectable GLP-1 medications used for weight loss, but they are not the same drug. Ozempic targets one receptor (GLP-1), while Mounjaro targets two (GLP-1 and GIP) - making it a dual-agonist with a broader metabolic effect.

Both are FDA-approved for type 2 diabetes. Ozempic's weight-loss version is Wegovy; Mounjaro's is Zepbound.

Understanding how GLP-1 medications work helps explain why these differences matter.

Our top 2 picks

Our two recommended GLP-1 providers, shown with the same verified pricing and ratings as our full comparison.

Our Top Pick
1
embody logo

Exceptional

9.8out of 10

Compounded GLP-1 from $49/month; not FDA-approved, free expedited delivery

Free expedited deliveryNo hidden fees
  • Compounded semaglutide ($49/mo) and tirzepatide ($99/mo) as shown on the homepage, Nov 16, 2026; not FDA-approved
  • Online intake, then a prescriber review by OpenLoop Health, a network of US-licensed doctors
  • Free expedited delivery (embody's words); the Terms do not guarantee a delivery timeline
  • No insurance required, no clinic visits; cancel at least 72 hours before the next billing date

from $49/month

Doctor-prescribed compounded GLP-1 treatment, not FDA-approved: semaglutide shown at $49/month and tirzepatide at $99/month on embody's homepage (Nov 16, 2026), no insurance required.

Read full embody review
2
altRx logo

Excellent

9.4out of 10

Most Comprehensive GLP-1 Medication Access

Transparent pricingNo insurance required
  • Compounded GLP-1 from $89/mo, GLP-1 + GIP from $149/mo
  • Brand-name options too: Zepbound and Wegovy
  • Clinician-guided - physician, PA, or nurse practitioner
  • Free shipping (about 5-7 days)

from $89/month

Affordable GLP-1 program from $89/month - compounded semaglutide and tirzepatide plus brand-name options - with clinician-guided, self-pay care and no insurance required.

Read full altRx review

How They Work Differently in the Body

Ozempic (semaglutide) mimics the GLP-1 hormone, slowing gastric emptying, reducing appetite, and improving insulin sensitivity. Mounjaro (tirzepatide) does all of this AND activates GIP receptors, which provide additional metabolic benefits including enhanced fat burning and improved nutrient processing.

This dual mechanism is why Mounjaro consistently outperforms Ozempic in clinical trials. For a deeper comparison of the active ingredients, see our tirzepatide vs semaglutide guide.

Weight Loss Results: Clinical Trial Data

The clinical data is clear. In the SURMOUNT trials, Mounjaro (tirzepatide) patients lost up to 22.5% of their body weight at the highest dose over 72 weeks.

In the STEP trials, Ozempic/Wegovy (semaglutide) patients lost approximately 15% of body weight over 68 weeks. For a 200-pound person, that's roughly 45 lbs with Mounjaro vs 30 lbs with Ozempic.

Both significantly outperform older weight loss medications and lifestyle changes alone. Read our semaglutide results timeline for week-by-week expectations.

Dosing Schedule and Administration

Both are once-weekly injections administered subcutaneously (typically in the abdomen, thigh, or upper arm). Ozempic starts at 0.25 mg and titrates up to a maximum of 2 mg.

Mounjaro starts at 2.5 mg and can increase to 15 mg. Both follow a gradual dose escalation to minimize side effects - typically increasing every 4 weeks.

The injection process is similar for both and takes only seconds. Most patients describe it as quick and nearly painless.

For details on what the first month looks like, see our first month guide.

What To Know Before Starting GLP-1 Treatment

Before starting GLP-1 treatment, it's important to understand a few key things. These medications require a prescription from a licensed clinician and aren't suitable for everyone. Some people may experience side effects, especially during the first few weeks as the body adjusts.

GLP-1s also tend to work best when combined with basic lifestyle habits like balanced nutrition and regular physical activity.

That's why choosing a provider that offers proper medical screening and ongoing follow-up support is essential for both safety and long-term success.

Woman preparing GLP-1 weight loss injection

Side Effects Compared

Both medications share the same primary side effects: nausea, vomiting, diarrhea, and constipation. These are most common during dose escalation and typically improve over time.

In clinical trials, Mounjaro had slightly higher rates of certain GI symptoms at its highest doses (15 mg), but at comparable doses, tolerability was similar. Serious but rare side effects for both include pancreatitis and gallbladder problems.

Both carry a boxed warning about thyroid C-cell tumors (observed in animal studies only). For detailed management strategies, read our side effects guide.

Cost: Brand-Name vs Compounded

At retail price without insurance, Ozempic costs approximately $900-$1,000/month and Mounjaro costs approximately $1,000-$1,100/month. Their weight-loss specific versions (Wegovy and Zepbound) are even more expensive at $1,000-$1,400/month.

However, most patients access these medications through telehealth providers offering compounded versions at a fraction of the cost: compounded semaglutide from $199/month and compounded tirzepatide from $300-$500/month. Both typically include medical consultations and home delivery.

For a detailed cost breakdown, see our semaglutide monthly cost guide and full pricing comparison.

Shop GLP-1 plans by product

The lowest published plans - cheapest first, conditions under each price.

Insurance Coverage

Insurance coverage varies significantly for both medications. Ozempic tends to have better insurance coverage because it's classified as a diabetes drug with a longer track record.

Mounjaro also has diabetes coverage. However, when prescribed specifically for weight loss (without a diabetes diagnosis), both medications are frequently excluded from formularies.

Wegovy and Zepbound face even more coverage barriers. For most patients paying out of pocket, compounded versions through telehealth providers are the most practical path.

See our guide on getting weight loss medication without insurance.

Can You Get Mounjaro or Ozempic Online?

Yes - both are available through licensed telehealth providers without in-person doctor visits. The process typically involves an online health evaluation, physician review, prescription, and home delivery within 3-7 days.

Most telehealth providers offer compounded versions of both semaglutide and tirzepatide. Some providers offer both medications, while others specialize in one. Compare providers that offer the medication you're interested in, or take our matching quiz for a personalized recommendation.

For a step-by-step walkthrough, read our guide on how to get Ozempic online.

Who Should Choose Mounjaro?

Mounjaro may be the better choice if you have significant weight to lose (50+ lbs), want the highest average weight loss based on clinical data, are interested in the dual-agonist mechanism, have type 2 diabetes alongside weight loss goals, or have tried semaglutide and hit a plateau. Mounjaro's dual mechanism provides additional metabolic benefits that some patients respond to better than semaglutide alone.

Who Should Choose Ozempic?

Ozempic/semaglutide may be the better choice if you prefer a medication with a longer track record and more real-world data, want the broadest availability through telehealth providers (compounded semaglutide is more widely available than compounded tirzepatide), are looking for the lowest cost option (compounded semaglutide starts around $199/month vs $300+ for tirzepatide), or have insurance that covers Ozempic but not Mounjaro.

Can You Switch Between Mounjaro and Ozempic?

Yes, switching between semaglutide and tirzepatide is possible and relatively common. Some patients start with Ozempic/semaglutide and switch to Mounjaro/tirzepatide if they plateau or want stronger results.

Others may switch from tirzepatide to semaglutide for cost reasons. Switching should always be done under medical supervision - your provider will determine the appropriate starting dose of the new medication.

Most telehealth providers can manage this transition as part of their ongoing care.

The Bottom Line: Mounjaro vs Ozempic

Both Mounjaro and Ozempic are proven, effective weight loss medications. Mounjaro has a clinical edge in average weight loss (22% vs 15%), while Ozempic has a longer track record, wider compounded availability, and lower compounded pricing.

The best choice depends on your weight loss goals, budget, insurance situation, and how your body responds. Many patients find success with either option.

The most important step is getting started with a licensed provider who can guide your treatment. Take our matching quiz to find the right provider for your needs, or compare all providers side by side.

Ready to compare weight loss providers?

See how top providers stack up on pricing, medical support, and treatment options.

Medical disclaimer

This page is general information about GLP-1 weight-loss medications such as semaglutide and tirzepatide, published to help you compare services. It is not medical advice, it does not create a doctor-patient relationship, and it is not a substitute for a consultation with a licensed clinician who knows your history. Treatments Hub is not a medical provider, pharmacy or clinic and does not prescribe, sell or dispense medication. Do not start, stop or change any treatment because of something you read here, and do not delay seeking care; in an emergency call 911.

Semaglutide and tirzepatide carry an FDA boxed warning about thyroid C-cell tumours seen in rodents and are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, nor for use in pregnancy. Compounded versions sold by telehealth providers are prepared by state-licensed pharmacies and are not FDA-approved products. Where a review or post on this page mentions weight lost, that is one person's result and is not typical; results vary widely.

Medical and scientific statements on this site are checked against the sources linked on the page by our medical content reviewer, who does not choose providers or set prices. Prices, plans and customer reviews are each provider's published figures and customers' own words on the dates stated. We may earn a commission from provider links. The full medical and advertising disclaimer explains all of this in detail.

Sources & medical references

Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.

  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
  2. 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
  3. 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
  4. 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
  5. 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
  6. 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
  7. 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)